May 2017, Volume 3, Issue 6

May 2017

Volume 3, Issue 6

This issue discusses the legacy of Agent Orange and hematologic malignancies, a debate over transplant in myelodysplastic syndromes, and more.

Table of Contents

May 2017 Issue

Molecular Stamp Collecting

Monday, May 1st, 2017
The great experimental physicist Ernest Rutherford (1871-1937) provocatively claimed, “All science is either physics … or stamp collecting.” Lord Rutherford intended his cocky quip as...

May 2017 Issue

ACS Announces Lane W. Adams Quality of Life Award Winners, 2017 Eric G. Neilson,...

Monday, May 1st, 2017
ACS Announces Lane W. Adams Quality of Life Award Winners The ACS honored six cancer caregivers with the Lane W. Adams Quality of Life Award,...

May 2017 Issue

Pulling Back the Curtain: Hetty Carraway, MD, MBA

Monday, May 1st, 2017
In this edition, Hetty Carraway, MD, MBA, talks about keeping medicine close to home and the importance of loving what you do. Dr. Carraway...

Agent Orange and Hematologic Malignancies: The Fog of War Still Hovers

Monday, May 1st, 2017
More than 40 years after the Vietnam War, the fog of Agent Orange hangs thick over veterans and those providing their medical care. Aging...

Should Patients With Myelodysplastic Syndromes Undergo Transplant?

Monday, May 1st, 2017
For patients with myelodysplastic syndromes (MDS), hematopoietic cell transplantation (HCT) is the only potentially curative option, but the rates of transplant-related morbidity and mortality...

May 2017 Issue

How to manage bleeding risk in a pregnant patient with factor XI deficiency?

Monday, May 1st, 2017
This month, Jean Marie Connors, MD, discusses how to manage the bleeding risk in a pregnant patient with factor XI deficiency. Also check out  next...

May 2017 Issue

Aplastic Anemia Nearly Triples Risk of VTE

Monday, May 1st, 2017
The systemic inflammation that characterizes aplastic anemia (AA) may also contribute to a greater risk of venous thromboembolism (VTE), giving patients with AA a...

Idelalisib Combination Improves PFS But Increases Infection Risk in Relapsed/Refractory CLL

Monday, May 1st, 2017
According to a randomized, placebo-controlled, phase III study published in the Lancet Oncology, adding idelalisib to the combination of bendamustine and rituximab (BR) nearly...

FDA Places Partial Clinical Hold on Selinexor for Multiple Myeloma

Monday, May 1st, 2017
The FDA placed clinical trials of selinexor on a partial hold, halting enrollment of new patients in the studies but allowing those who have...

FDA Clears Device That Touts “Fast and Virtually Painless” Blood Draw

Monday, May 1st, 2017
The FDA granted 510(k) clearance to TAP, a blood collection device that is placed on the upper arm and collects 100 µL of capillary...

FDA Grants Marketing Authorization for Personal Genetic Risk Tests

Monday, May 1st, 2017
The FDA has approved marketing for 23andMe Personal Genome Service Genetic Health Risk (GHR) tests, the first direct-to-consumer tests that analyze DNA from users’...

Development of CAR T-Cell Therapy for Acute Lymphocytic Leukemia Shut Down Following Clinical Holds

Monday, May 1st, 2017
Juno Therapeutics, the manufacturer of the experimental chimeric antigen receptor (CAR) therapy JCAR015 for patients with relapsed acute lymphocytic leukemia, announced that it will...

Trials of Vadastuximab Talirine to Resume After FDA Clinical Hold

Monday, May 1st, 2017
The FDA lifted its clinical hold on early-stage studies of vadastuximab talirine for AML after halting them in early January following four patient deaths. Seattle...

Rivaroxaban Beats Aspirin in Reducing Risk of Recurrent VTE, Even at Lower Doses

Monday, May 1st, 2017
Patients with venous thromboembolism (VTE) require anticoagulation, but concerns about bleeding have complicated decisions about using higher- or lower-intensity anticoagulation or aspirin for subsequent...

FDA Grants Priority Review of Enasidenib for Acute Myeloid Leukemia

Monday, May 1st, 2017
The FDA granted priority review of enasidenib for patients with relapsed/refractory IDH2-mutated acute myeloid leukemia (AML). The decision was based on results of the single-arm,...

FDA Approves Pembrolizumab for Classic Hodgkin Lymphoma

Monday, May 1st, 2017
The FDA approved the anti-PD-1 monoclonal antibody pembrolizumab for adults and children with classic Hodgkin lymphoma who are refractory to treatment or who have...

FDA Approves Lenalidomide for Maintenance Therapy in Multiple Myeloma

Monday, May 1st, 2017
The U.S. Food and Drug Administration (FDA) expanded the approval of lenalidomide to include maintenance therapy for patients with multiple myeloma (MM) who have...

Webinar Preview for 2017 ASH Meeting, ASH Global Capacity-Building Showcase, and more

Monday, May 1st, 2017
Webinar Preview: Series for the 2017 ASH Meeting on Hematologic Malignancies A special webinar series previewing the 2017 ASH Meeting on Hematologic Malignancies is...
WIB_icon

Weighing the Risks and Benefits of Nivolumab in Patients With Hodgkin Lymphoma Undergoing AlloHCT

Monday, May 1st, 2017
For patients with Hodgkin lymphoma (HL), allogeneic hematopoietic cell transplantation (alloHCT) can induce long-term disease control; however, relapse is common and rates of 3-year...
WIB_icon

Pembrolizumab Induces Remission in Small Cohort of Patients With Natural Killer/T-Cell Lymphomas

Monday, May 1st, 2017
For the 20 to 40 percent of patients with natural killer (NK)/T-cell lymphomas who do not respond to regimens such as SMILE (dexamethasone, methotrexate,...
WIB_icon

Venetoclax Plus Obinutuzumab Effective in Older Adults With CLL and Comorbidities

Monday, May 1st, 2017
Patients with chronic lymphocytic leukemia (CLL) are often older at the time of diagnosis (median age = 72 years), and typically receive treatment for...
WIB_icon

Is Ibrutinib Tied to Ventricular Arrhythmias?

Monday, May 1st, 2017
Previous studies have indicated that treatment with ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is associated with a 5 to 15 percent increase in...

Investigating Trends in Survival Outcomes Among the Oldest Patients with DLBCL

Monday, May 1st, 2017
The probability of developing non-Hodgkin lymphoma (NHL) increases with age. Thus, as the U.S. population ages, a greater number of patients are at risk...

May 2017 Issue

Investigational CAR T-Cell Therapy Improves Objective Response Rate in Patients With Aggressive NHL

Monday, May 1st, 2017
At the 2017 AACR Annual Meeting, Frederick L. Locke, MD, from the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida, and...

Investigational Drug TEW-7197 Improves Myeloma Outcomes Both as Single Agent and in Combination With...

Monday, May 1st, 2017
TGF-β, a multifunctional cytokine, is produced in multiple myeloma (MM) cells and cells in the bone marrow (BM) tumor microenvironment (TME), where it also...

BION-1301 May Improve Survival and Inhibit Treatment Resistance for Patients With Myeloma

Monday, May 1st, 2017
In a preclinical study presented at the 2017 AACR Annual Meeting, BION-1301, an anti-human APRIL blocking antibody, inhibited the survival of multiple myeloma (MM)...

CHRONOS-1: Copanlisib Shows Promise for Patients With Relapsed/Refractory Indolent B-Cell NHL

Monday, May 1st, 2017
Patients with relapsed/refractory indolent B-cell lymphomas often have limited options beyond standard therapies once their disease progresses. Copanlisib, an intravenously administered pan-class I phosphatidylinositol...

SHARE